Single Dose Crossover Comparative Bioavailability Study of Deferiprone 600 mg Delayed Release Tablets Versus Deferiprone Oral Solution in Healthy Male and Female Volunteers Following a 1200 mg Dose

Trial Profile

Single Dose Crossover Comparative Bioavailability Study of Deferiprone 600 mg Delayed Release Tablets Versus Deferiprone Oral Solution in Healthy Male and Female Volunteers Following a 1200 mg Dose

Completed
Phase of Trial: Phase I

Latest Information Update: 15 May 2016

At a glance

  • Drugs Deferiprone (Primary) ; Deferiprone
  • Indications Iron overload; Pantothenate kinase-associated neurodegeneration
  • Focus Pharmacokinetics
  • Sponsors ApoPharma
  • Most Recent Events

    • 14 Jul 2015 Status changed from recruiting to completed as reported byClinicalTrials.gov record.
    • 26 May 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 15 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top